KOSDAQBiotech & Pharma251120

BIO-FD&C

₩7,310▼ 1.48%2026-11-18 close
Market Cap
₩63.6B
Turnover
₩71,305,450
Volume
9.7K
Shares out.
8.7M
PER
13.6×
PBR
1.0×
EPS
₩652
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Plant-cell PDRN growth meets quarterly volatility

Skin-booster and cosmetic-ingredient sales built on the plant-cell platform lifted 2025 annual results, but revenue and profit both fell in the third quarter of 2026, leaving quarterly volatility as the main open issue for BIO-FD&C.

  1. 1

    2025 revenue rose 19.4% year on year to KRW 19.2 billion, and operating profit rose 28.9% to KRW 6.25 billion.

  2. 2

    Third-quarter 2026 revenue fell 16.0% year on year to KRW 4.26 billion, and net income attributable to controlling shareholders fell 43.9% to KRW 1.09 billion.

  3. 3

    Operating profit of KRW 2.1 billion in the second quarter of 2026 rose 105.0% from the prior quarter and was the largest of the last five quarters, but it fell back to KRW 1.23 billion in the third quarter.

  4. 4

    At year-end 2025, total equity was KRW 69.8 billion, total liabilities were KRW 3.65 billion, and the debt ratio was 5.2%.

  5. 5

    The company has not fixed when new businesses such as microneedle patches will contribute meaningful revenue, so segment disclosures in the next annual report are the next checkpoint.

02

Business structure

BIO-FD&C uses a plant-cell culture platform to produce bioactive materials such as growth factors and plant-based PDRN, and supplies them as finished products and ingredients. The company listed on KOSDAQ in February 2022 and has built its business around cosmetic ingredients and clinic-use skin boosters.

Its GFX line, finished products that use growth factors as the raw material, is the largest revenue segment.

Segment mix differs by source: a tally based on Q2 2026 revenue shows GFX at 58%, plant cells at 19%, growth factors at 14%, PCX at 6% and others at 1%, while a March 2026 tally from another data provider shows GFX at 49%, plant-cell extract at 13%, PCX at 10%, growth-factor peptides at 9% and others at 19%.

The company makes PhytoPDRN directly from plant cells in high-purity, low-molecular form to serve vegan and clean-beauty demand. Its customers include clinics and domestic and overseas beauty brands, and OEM and ODM orders are reported to be expanding.

A 2025 report said the company co-developed plant-derived PDRN prototypes with Kolmar Korea, a major cosmetics OEM player, and planned supply to domestic and overseas cosmetic makers from 2026.

The microneedle patch business rests on a production-equipment contract signed in July 2023; the company estimated about KRW 20 billion in capex for expansion once sales take off, with the timing of that spending unclear.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.1B₩1.7B33.4%
2025Q4₩5.1B₩1.3B25.0%
2026Q1₩4B₩1B25.7%
2026Q2₩5.4B₩2.1B39.2%
2026Q3₩4.3B₩1.2B28.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩15.9B₩4.9B₩4.3B30.8%8.2%11.4%
2023₩15.6B₩5B₩5.6B32.3%9.5%7.2%
2024₩16.1B₩4.9B₩4.5B30.2%7.1%6.6%
2025₩19.2B₩6.3B₩6.7B32.6%9.6%5.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue moved from KRW 15.9 billion in 2022 to KRW 15.6 billion in 2023 (down 1.7% year on year), then rose to KRW 16.1 billion in 2024 (up 3.0%) and KRW 19.2 billion in 2025 (up 19.4%). Revenue rose in 2024 and 2025, and 2025 was the largest year in the 2022–2025 period while 2023 was the smallest.

Operating profit was KRW 4.88 billion in 2022, KRW 5.03 billion in 2023 (up 3.1%), KRW 4.85 billion in 2024 (down 3.6%) and KRW 6.25 billion in 2025 (up 28.9%), with 2025 the largest and 2024 the smallest year. The operating margin stayed around 30%, at 30.8%, 32.3%, 30.2% and 32.6% from 2022 to 2025.

In 2025 the margin rose from 30.2% to 32.6% as revenue grew, so operating profit grew faster than revenue. Net income attributable to controlling shareholders was KRW 4.34 billion in 2022, KRW 5.59 billion in 2023 (up 28.8%), KRW 4.5 billion in 2024 (down 19.4%) and KRW 6.67 billion in 2025 (up 48.1%).

In 2023 that figure exceeded operating profit of KRW 5.03 billion, which suggests non-operating items contributed; the detail should be checked in the annual report notes. Net income including non-controlling interests equaled the controlling-shareholder figure in each year and was KRW 6.67 billion in 2025.

The company attributed the 2025 improvement to higher GFX revenue. Operating cash flow rose from KRW 5.57 billion in 2022 to KRW 7.28 billion in 2025.

On a quarterly basis, third-quarter 2025 revenue was KRW 5.07 billion with operating profit of KRW 1.7 billion; fourth-quarter 2025 revenue was KRW 5.1 billion (up 0.6% from the prior quarter) with operating profit of KRW 1.27 billion (down 24.8%).

First-quarter 2026 revenue fell to KRW 4 billion (down 21.7%) with operating profit of KRW 1.03 billion (down 19.5%). Second-quarter 2026 revenue recovered to KRW 5.36 billion (up 34.1%) and operating profit rose to KRW 2.1 billion (up 105.0%).

According to an Etoday report, the company put the second-quarter operating margin at 39.2% and credited strong skin-booster sales.

Third-quarter 2026 revenue was KRW 4.26 billion (down 20.6% from the prior quarter and down 16.0% year on year), operating profit was KRW 1.23 billion (down 41.6% and down 27.5%), and net income attributable to controlling shareholders was KRW 1.09 billion (down 44.8% and down 43.9%).

Over the latest four quarters (Q4 2025 to Q3 2026), net income attributable to controlling shareholders totaled KRW 5.56 billion. Whether the second-quarter jump reflected one-off items should be checked against quarterly detail.

05

Industry analysis

PDRN (polydeoxyribonucleotide) is a raw material attracting attention for regeneration and anti-inflammatory uses.

According to a August 2025 Hana Securities report citing Grand View Research estimates, the global PDRN market is projected to grow about 43% a year over 2024–2031, and the skin-booster segment about 14% a year over 2024–2030. These are private research estimates and should be read as directional.

The same report said a 2025 second-quarter pilot test by the company showed plant-based PDRN matched or exceeded the regeneration and anti-inflammatory effects of animal-derived PDRN, a result based on the company's own testing.

In skin boosters, the company competes with animal-derived PDRN products through clinic channels; in cosmetic OEM and ODM work it stresses the safety and cost competitiveness of plant-derived ingredients. The company says it secured plant-cell cryopreservation technology, a first in Korea.

Among listed peers in the same sector, PharmaResearch is a comparison point in skin boosters. The company has said it is shifting from an R&D-centered structure toward product- and brand-centered, higher-margin operations, and whether that shift shows up in profits should be checked in segment profit trends.

Sector supply-demand and pricing indicators are not sufficiently established in the sources, so the industry cycle position cannot be stated with confidence.

06

Outlook

In a 2025 interview, the company said PDRN revenue would take off in the second half of 2025 and expected more than KRW 5 billion in PDRN ingredient and product revenue by 2026. It said US exports would be reflected in revenue once shipments began in the second half.

At its second-quarter 2026 results, the company said it expected solid growth to continue in the second half, but third-quarter 2026 revenue and operating profit both fell from the prior quarter, so the gap between that message and the actual trend is a reference point for the second half.

The company said it would widen its plant-based PDRN product lineup with support from government national research projects.

A 2024 report said microneedle-patch cosmetics and medical devices could appear as early as 2025, while a 2025 report described the patch business as just before full-scale sales, with expansion decisions to follow market response. A 2024 report expected a ginseng cell-line health functional food as early as 2025.

The company also cited a biopharmaceutical pipeline, including treatments for gastritis, gastric cancer and urinary incontinence and a cervical cancer vaccine, with technology transfer and CDMO entry under review for the longer term.

The actual revenue contribution of these businesses should be checked in the annual report notes and segment disclosures. The next periodic report is the 2026 annual report, and its segment revenue and operating margin are the next checkpoint for the business direction.

07

Valuation

PER
13.6×
PBR
1.0×
ROE
7.8%
EPS
₩652
BPS
₩8,683
Dividend per share
₩0

Valuation is best read against earnings scale and net asset value. Net income attributable to controlling shareholders rose 48.1% in 2025, but fell 43.9% year on year in the third quarter of 2026, so earnings multiples shift a lot with the quarterly trend.

On the latest four quarters' total of KRW 5.56 billion, the same share price maps to a lower multiple when earnings recover and a higher one when they fall. The price-to-book ratio sits near book value, close to year-end 2025 total equity of KRW 69.8 billion, which means the premium over net assets is not large.

Much of the asset base is cash and deposits, which makes the book value relatively simple to read. The company recorded zero dividends per share from 2021 to 2024, so shareholder returns through dividend yield are low and below the sector average.

Over several years, operating profit and net income both rose from 2022 to 2025, a clear direction of earnings recovery. The direction of valuation will still depend on the earnings mix and new-business results, so the next annual report's earnings composition should be read alongside.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Sharp second-quarter 2026 profit jump

Second-quarter 2026 revenue rose 34.1% from the prior quarter to KRW 5.36 billion, and operating profit rose 105.0% to KRW 2.1 billion. According to an Etoday report, the company put the quarter's operating margin at 39.2% and credited strong skin-booster sales.

The company said its use of plant-cell-derived growth factors and PDRN in skin boosters met market demand. The quarter was the strongest of the last five disclosed periods, which supports the case for a structural improvement.

2025 earnings recovery and high operating margin

2025 revenue rose 19.4% to KRW 19.2 billion and operating profit rose 28.9% to KRW 6.25 billion. The operating margin of 32.6% was the highest of the four years from 2022 to 2025. Operating cash flow in 2025 was KRW 7.28 billion, the largest of the four years.

The company attributed the improvement to higher GFX revenue, and cash generation grew alongside profit, which is cited as a strength.

Plant-based PDRN demand and overseas inquiries

In a 2025 interview the company said it had begun supplying raw materials to major domestic cosmetics makers and was receiving overseas inquiries. A KRW 2 billion plant-derived PDRN supply contract aimed at US exports was also reported.

A prototype co-developed with Kolmar Korea is cited as evidence of demand expansion. On the balance sheet, year-end 2025 total equity of KRW 69.8 billion and a 5.2% debt ratio give the company room to fund new businesses.

09

Bear factors

Quarterly profit turns down again

First-quarter 2026 revenue fell 21.7% to KRW 4 billion, and third-quarter revenue fell 20.6% from the prior quarter to KRW 4.26 billion. Net income attributable to controlling shareholders fell 44.8% to KRW 1.09 billion in the third quarter, reversing much of the second-quarter rebound.

The company said at its second-quarter results that growth would continue in the second half, but revenue and profit both declined in the third quarter. A report also said the company expressed regret over the recent share-price weakness.

Gap with past growth estimates

According to an IB Tomato report, the revenue estimates in the IPO registration statement were KRW 25.6 billion for 2022, KRW 36.4 billion for 2023 and KRW 48.1 billion for 2024, while actual revenue was KRW 15.9 billion, KRW 15.6 billion and KRW 16.1 billion.

The same report noted that only about 12% of the IPO facility funds had been used. The gap shows growth ran slower than the original plan, and whether the recent recovery is durable enough to close it remains to be confirmed.

Uncertain timing of new-business revenue

The microneedle patch business has advanced through a July 2023 production-equipment contract and a patent obtained in April 2025, but it was still described as before full-scale sales. Expansion was estimated to need about KRW 20 billion in capex, with the timing of that spending reported as unclear.

Health functional foods and biopharmaceuticals remain at the planning stage, and their revenue contribution is not shown in public disclosures at a meaningful scale. Until new businesses generate sales, growth depends on skin boosters and PDRN ingredients.

10

Risk factors

Quarterly earnings volatility

Quarterly operating profit moved between the KRW 1 billion range and the low KRW 2 billion range from Q3 2025 to Q3 2026. Quarterly revenue can swing sharply with order and shipment timing, so one quarter's rebound is hard to read as an annual trend. Segment revenue disclosures are needed to confirm continuity.

New-business investment burden and capex

A report said expansion of the microneedle patch business could require about KRW 20 billion in capex. At the end of the third quarter of 2025, cash and cash equivalents were KRW 11.2 billion and short-term financial instruments were KRW 40 billion.

If the investment does not translate into sales, the return on those funds could weaken, and the scale and timing of spending should be checked in company disclosures.

Approvals and competition

The company said in its IPO use-of-proceeds plan that it intended to secure a medical-device GMP facility. Cosmetic ingredients, medical devices and biopharmaceuticals each follow separate approval regimes.

Against animal-derived PDRN products, plant-derived ingredients must keep a clear edge in efficacy and cost, and that edge may depend on further test results.

11

What to watch next

  1. Early February 2027 (approx.)

    Preliminary 2026 full-year results. The 2025 full-year results were disclosed on February 9, 2026, so a similar-timed release would show the change in revenue and operating profit versus 2025.

  2. Late March 2027 (approx.)

    Submission of the 2026 annual report. It shows segment revenue, new-business costs, cash flow and non-operating items, and may identify the drivers of the third-quarter 2026 profit decline.

  3. Around March 2027 (approx.)

    Annual general meeting. Financial statements were approved at the March 2026 meeting, and whether a dividend is declared is a checkpoint for the shareholder-return picture.

  4. Mid-May 2027 (approx.)

    Q1 2027 quarterly report. Compared with Q1 2026 revenue of KRW 4 billion and operating profit of KRW 1.03 billion, it shows whether the quarterly trend is continuing.

  5. First half of 2027 (timing not fixed)

    Whether the company decides on the microneedle patch expansion (estimated capex around KRW 20 billion). Timing has been reported as unclear, so company disclosures and IR updates should be checked for a decision.

12

Overall view

BIO-FD&C is a company whose skin-booster and cosmetic-ingredient business, built on a plant-cell platform, lifted both annual revenue and operating profit in 2025. Year-end 2025 total equity of KRW 69.8 billion and a 5.2% debt ratio indicate a light financial burden.

Second-quarter 2026 operating profit of KRW 2.1 billion was the largest of the disclosed quarters, but revenue and profit both declined in the third quarter of 2026.

Bullish factors include growing plant-based PDRN demand, overseas inquiries and a solid balance sheet, while bearish factors include quarterly earnings volatility, a gap with past growth estimates and uncertain timing for new-business revenue.

Because both sets of factors coexist, the balance between them should be judged on the earnings trend. The next checkpoints are the preliminary 2026 full-year results (early February 2027, approx.) and the 2026 annual report (late March 2027, approx.), focusing on segment revenue and operating margin.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. hanaw.com
  3. hanaw.com
  4. digitaltoday.co.kr
  5. butler.works
  6. ibtomato.com
  7. etoday.co.kr
  8. news.mt.co.kr
  9. newstomato.com
  10. pharm.edaily.co.kr
  11. jobkorea.co.kr
  12. news.nate.com
  13. jobkorea.co.kr
  14. news.nate.com
  15. judal.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis